Adverse event reports of seizure for insomnia medication from 1967 to 2023
Insomnia may negatively impact seizure control; however, the corresponding evidence remains limited. This study analyzed the seizure risk associated with various insomnia medications using a comprehensive pharmacovigilance database and identified safe ...
Tae Hyeon Kim +13 more
doaj +1 more source
Dual Orexin Receptor Antagonists (DORAs) in the Management of Climacteric Insomnia: A Scoping Review
This scoping review aims to map the available scientific evidence regarding the efficacy, safety, and tolerability of Dual Orexin Receptor Antagonists (DORAs)—specifically suvorexant, lemborexant, and daridorexant—in treating insomnia among women during ...
Ester Saraiva Carvalho Feitosa
core
Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in Treatment of Insomnia. [PDF]
Sarathi Chakraborty D +2 more
europepmc +1 more source
Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis. [PDF]
Xue T +7 more
europepmc +1 more source
The excitatory neuropeptides orexin-A and-B interact with their target G protein-coupled receptors (GPCRs), the orexin 1 and orexin 2 (OX1 and OX2) receptors, which are widely expressed throughout the central nervous system.
Decker, Michael +4 more
core +1 more source
Hypnotic prescriptions in Japan may be shifting from benzodiazepine receptor agonists to other types of hypnotics, melatonin receptor agonists, and orexin receptor antagonists. [PDF]
Usui K +7 more
europepmc +1 more source
Dual orexin receptor antagonists for insomnia in youth with neurodevelopmental disorders: a case series and review. [PDF]
Besterman AD, Jeste SS.
europepmc +1 more source
Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant. [PDF]
Khazaie H +4 more
europepmc +1 more source
Although three dual orexin receptor antagonists (DORAs, daridorexant, lemborexant, and suvorexant) have been launched for adults with insomnia, because it is unclear which DORAs had favorable risk-benefit balance for the people, we will conduct the ...
Taro Kishi
core +1 more source

